HRP20210611T1 - Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala - Google Patents
Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala Download PDFInfo
- Publication number
- HRP20210611T1 HRP20210611T1 HRP20210611TT HRP20210611T HRP20210611T1 HR P20210611 T1 HRP20210611 T1 HR P20210611T1 HR P20210611T T HRP20210611T T HR P20210611TT HR P20210611 T HRP20210611 T HR P20210611T HR P20210611 T1 HRP20210611 T1 HR P20210611T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- protofibril
- stabilized
- monomer
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| EP10739701.0A EP2448968B1 (en) | 2009-06-29 | 2010-06-29 | ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210611T1 true HRP20210611T1 (hr) | 2021-05-28 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210611TT HRP20210611T1 (hr) | 2009-06-29 | 2010-06-29 | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3892633A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2012532094A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010267640B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2765602C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1124034T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2448968T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2864049T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20210611T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE053949T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2448968T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2448968T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2448968T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2448968T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202100237T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011001366A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP2325209A3 (en) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
| ES2661925T3 (es) | 2010-02-26 | 2018-04-04 | Bioarctic Ab | Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías |
| AU2012228236B2 (en) * | 2011-03-16 | 2016-10-27 | Vivoryon Therapeutics N.V. | Diagnostic antibody assay |
| JO3537B1 (ar) | 2014-07-10 | 2020-07-05 | Bioarctic Neuroscience Ab | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| SG10201912842VA (en) | 2016-07-14 | 2020-02-27 | Bioarctic Ab | Brain delivery protein |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2019309938A1 (en) | 2018-07-24 | 2021-03-11 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| EP3998280A4 (en) * | 2019-07-08 | 2023-06-21 | TERUMO Kabushiki Kaisha | HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| AU2021278935A1 (en) | 2020-05-26 | 2022-12-08 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| PH12022552829A1 (en) | 2020-06-26 | 2023-06-14 | Bioarctic Ab | Alpha-synuclein protofibril-binding antibodies |
| JP2024525559A (ja) | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| WO2023034230A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Mangement Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| AU2023410175A1 (en) | 2022-12-22 | 2025-07-03 | Bioarctic Ab | Antibody which binds to abetape3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| DE60016227T2 (de) * | 1999-08-04 | 2005-12-15 | Northwestern University, Evanston | Globularer aufbau vom amyloid-beta- protein und deren verwendungen |
| EP1309341A2 (en) * | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| JP4633788B2 (ja) * | 2004-04-13 | 2011-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｐ−セレクチン抗体 |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| TWI355389B (en) * | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
| EP2325209A3 (en) * | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
| PT2207568T (pt) * | 2007-11-16 | 2017-09-01 | Univ Rockefeller | Anticorpos específicos para a forma de protofibrilha da proteína beta-amilóide |
| EP3470079A1 (en) * | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
-
2010
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK2448968T3 (da) | 2021-04-12 |
| WO2011001366A1 (en) | 2011-01-06 |
| AU2010267640A1 (en) | 2012-01-19 |
| JP2017197531A (ja) | 2017-11-02 |
| SMT202100237T1 (it) | 2021-05-07 |
| EP2448968B1 (en) | 2021-01-27 |
| JP6884025B2 (ja) | 2021-06-09 |
| CY1124034T1 (el) | 2022-05-27 |
| ES2864049T3 (es) | 2021-10-13 |
| EP2448968A1 (en) | 2012-05-09 |
| JP2019218362A (ja) | 2019-12-26 |
| CA2765602C (en) | 2021-05-25 |
| PL2448968T3 (pl) | 2021-09-13 |
| SI2448968T1 (sl) | 2021-07-30 |
| CA2765602A1 (en) | 2011-01-06 |
| EP3892633A1 (en) | 2021-10-13 |
| US20120100129A1 (en) | 2012-04-26 |
| PT2448968T (pt) | 2021-04-30 |
| JP2012532094A (ja) | 2012-12-13 |
| AU2010267640B2 (en) | 2015-03-05 |
| US20230295283A1 (en) | 2023-09-21 |
| HUE053949T2 (hu) | 2021-08-30 |
| LT2448968T (lt) | 2021-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210611T1 (hr) | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala | |
| Iulita et al. | Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study | |
| Brännström et al. | A generic method for design of oligomer-specific antibodies | |
| TWI549966B (zh) | 測定澱粉樣肽之抗體、套組及方法 | |
| AR078650A1 (es) | Anticuerpo de union a il-1 beta | |
| JP2009525758A5 (cg-RX-API-DMAC7.html) | ||
| UA105768C2 (uk) | Антитіла до рецептора кінцевих продуктів глибокого глікування (rage) і їх застосування | |
| DE69940364D1 (de) | Fab Fragmentbibliotheken und Verfahren für deren Verwendung | |
| NO20083805L (no) | Anvendelse av et antistoff som binder Aβ-peptidsekvenser | |
| JP2007527865A5 (cg-RX-API-DMAC7.html) | ||
| BRPI1015088A2 (pt) | peptídeo antigênio ou um fragmento funcional deste, composição farmacêutica, métodos para o tratamento de uma doença ou distúrbio neurodegenerativos tal como tauopatia, para induzir uma resposta imune em um animal, para diagnosticar uma doença, distúrbio ou condição e uma predisposição a doença, distúrbio ou condição, para monitorar a doença residual mínima em um paciente e para prever a receptividade de um paciente, anticorpo, kit de teste, epítopo e linha celular. | |
| JP2017524725A5 (cg-RX-API-DMAC7.html) | ||
| DE69417417D1 (de) | Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen | |
| WO2009006347A3 (en) | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes | |
| WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
| WO2010039873A3 (en) | Humanized endoglin antibodies | |
| JP2007535930A5 (cg-RX-API-DMAC7.html) | ||
| CL2007003771A1 (es) | Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an | |
| BRPI0607486B8 (pt) | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| WO2012009442A3 (en) | Anti-addl monoclonal antibody and uses thereof | |
| WO2007050359A8 (en) | Anti-addl monoclonal antibody and use thereof | |
| JP2012532094A5 (cg-RX-API-DMAC7.html) | ||
| EP1886140A4 (en) | IMMUNOLOGICAL ASSAYS AND ANTIBODIES FOR ANTI-MÜLLERIAN HORMONE | |
| EP4121021A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES ASSOCIATED WITH DIABETES MELLITUS TYPE I AND TYPE II AND THYROID DISEASES | |
| WO2018049053A3 (en) | Peptides and uses thereof for diagnosing and treating myasthenia gravis |